Cellarity

Cellarity is a clinical-stage biotechnology company that leverages a proprietary AI-driven platform to design medicines based on cellular behavior rather than single molecular targets. By 2026, Cellarity has solidified its position as a leader in 'Digital Biology,' utilizing high-dimensional single-cell transcriptomics to map how disease disrupts cell states. Unlike traditional target-based approaches that focus on a single protein, Cellarity's architecture uses deep learning to understand the 'cell state transition'—the complex interplay of gene networks that define health versus disease. This allows for the discovery of small molecules that can reprogram diseased cells back to a healthy state. The platform integrates massive biological datasets with predictive algorithms, enabling the identification of novel therapeutic candidates across diverse therapeutic areas including hematology, metabolic diseases, and oncology. Their approach significantly reduces the biological uncertainty inherent in drug discovery by focusing on the fundamental unit of life: the cell. As a Flagship Pioneering company, Cellarity represents a paradigm shift toward systems-level pharmacology, where AI acts as the primary bridge between complex biological data and actionable drug leads.